Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Table 4. SVR rates in genotype 1-infected patients treated with PegIFN/RBV +/- BOC or TVR

for Health Care Providers

Table 4. SVR rates in genotype 1-infected patients treated with PegIFN/RBV +/- BOC or TVR

Therapy against Hepatitis C in Patients with Genotype 1 Infection

Study cohort, NSVR to PI/PegIFN/RBV (arm 1 of trial)SVR to PI/PegIFN/RBV (arm 2 of trial)SVR with PegIFN/RBV
BOC, boceprevir; eRVR, extended rapid virologic response; HCV, hepatitis C virus; PegIFN, peginterferon alfa; PI, protease inhibitor; RBV, ribavirin; RGT, response-guided therapy; SVR, sustained virologic response; TVR, telaprevir.
Treatment-naive
BOC (SPRINT-2), SVR% 63 66 38
N = 1,099 (11) BOC/PegIFN/RBV RGT BOC/PegIFN/RBV 44 weeks PegIFN/RBV 48 weeks
TVR (ADVANCE), SVR% 69 75 44
N = 1,088 (12) TVR for 8 weeks/PegIFN/RBV RGT TVR for 12 weeks/PegIFN/RBV RGT PegIFN/RBV 48 weeks
TVR (ILLUMINATE), SVR% 71 73 NA
N = 540 (49) TVR for 12 weeks/PegIFN/RBV (24 total weeks) if eRVR TVR for 12 weeks/PegIFN/RBV(48 total weeks) if eRVR -
Treatment-experienced
TVR (REALIZE), SVR% overall - -
N = 662 (13) NA 64-66 17
TVR for 12 weeks/PegIFN/RBV (48 weeks total)
Prior relapsers (SVR%) - 83-88 24
Prior partial responders (SVR%) - 54-59 15
Prior null responders (SVR%) - 29-33 5
BOC (RESPOND-2), SVR% overall
N = 403 (14) 59 66 21
BOC/PegIFN/RBV (48 weeks total)
Prior relapsers (SVR%) 69 75 29
Prior partial responders (SVR%) 40 52 7